BTMD Valuation

Biote Corp

Add to Watchlist

Advanced Chart

2.920

-0.94(-24.352%)1D

Overview
Forecast
Valuation
Earnings

BTMD Relative Valuation

BTMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BTMD is overvalued; if below, it's undervalued.

Historical Valuation

Biote Corp (BTMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.63 is considered Fairly compared with the five-year average of 3.16. The fair price of Biote Corp (BTMD) is between 1.44 to 4.71 according to relative valuation methord.

Relative Value

Fair Zone

1.44-4.71

Current Price：3.86

Fair

9.97

Trailing

Forward

3.25

EV/EBITDA

Biote Corp. (BTMD) has a current EV/EBITDA of 3.25. The 5-year average EV/EBITDA is 2.12. The thresholds are as follows: Strongly Undervalued below -0.99, Undervalued between -0.99 and 0.56, Fairly Valued between 3.68 and 0.56, Overvalued between 3.68 and 5.23, and Strongly Overvalued above 5.23. The current Forward EV/EBITDA of 3.25 falls within the Historic Trend Line -Fairly Valued range.

4.40

EV/EBIT

Biote Corp. (BTMD) has a current EV/EBIT of 4.40. The 5-year average EV/EBIT is 2.95. The thresholds are as follows: Strongly Undervalued below -1.39, Undervalued between -1.39 and 0.78, Fairly Valued between 5.12 and 0.78, Overvalued between 5.12 and 7.29, and Strongly Overvalued above 7.29. The current Forward EV/EBIT of 4.40 falls within the Historic Trend Line -Fairly Valued range.

0.63

Biote Corp. (BTMD) has a current PS of 0.63. The 5-year average PS is 0.54. The thresholds are as follows: Strongly Undervalued below -0.13, Undervalued between -0.13 and 0.21, Fairly Valued between 0.87 and 0.21, Overvalued between 0.87 and 1.20, and Strongly Overvalued above 1.20. The current Forward PS of 0.63 falls within the Historic Trend Line -Fairly Valued range.

3.77

P/OCF

Biote Corp. (BTMD) has a current P/OCF of 3.77. The 5-year average P/OCF is 2.73. The thresholds are as follows: Strongly Undervalued below -0.76, Undervalued between -0.76 and 0.99, Fairly Valued between 4.47 and 0.99, Overvalued between 4.47 and 6.21, and Strongly Overvalued above 6.21. The current Forward P/OCF of 3.77 falls within the Historic Trend Line -Fairly Valued range.

4.02

P/FCF

Biote Corp. (BTMD) has a current P/FCF of 4.02. The 5-year average P/FCF is 3.02. The thresholds are as follows: Strongly Undervalued below -0.55, Undervalued between -0.55 and 1.24, Fairly Valued between 4.80 and 1.24, Overvalued between 4.80 and 6.59, and Strongly Overvalued above 6.59. The current Forward P/FCF of 4.02 falls within the Historic Trend Line -Fairly Valued range.

Biote Corp (BTMD) has a current Price-to-Book (P/B) ratio of -1.37. Compared to its 3-year average P/B ratio of -2.54 , the current P/B ratio is approximately -45.92% higher. Relative to its 5-year average P/B ratio of -2.16, the current P/B ratio is about -36.44% higher. Biote Corp (BTMD) has a Forward Free Cash Flow (FCF) yield of approximately 28.17%. Compared to its 3-year average FCF yield of 8.95%, the current FCF yield is approximately 214.61% lower. Relative to its 5-year average FCF yield of 10.10% , the current FCF yield is about 179.01% lower.

-1.37

P/B

Median3y

-2.54

Median5y

-2.16

28.17

FCF Yield

Median3y

8.95

Median5y

10.10

Competitors Valuation Multiple

The average P/S ratio for BTMD's competitors is 0.29, providing a benchmark for relative valuation. Biote Corp Corp (BTMD) exhibits a P/S ratio of 0.58, which is 96.51% above the industry average. Given its robust revenue growth of -0.62%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Viemed Healthcare Inc

SunLink Health Systems Inc

Community Health Systems Inc

National Healthcare Corp

Loss

25.75%

1.49B

Performance Decomposition

Market capitalization of BTMD decreased by 38.54% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.53 to 4.88.

The secondary factor is the Revenue Growth, contributed -0.62%to the performance.

Overall, the performance of BTMD in the past 1 year is driven by P/E Change. Which is more unsustainable.

-0.62%

49.17M → 48.86M

Revenue Growth

-130.61%

-21.30 → 6.52

Margin Expansion

92.69%

2.53 → 4.88

P/E Change

-38.54%